{
    "clinical_study": {
        "@rank": "1646", 
        "acronym": "Near- Rwanda", 
        "arm_group": [
            {
                "arm_group_label": "Rilpivirine/Emtricitabine/Tenofovir", 
                "arm_group_type": "Active Comparator", 
                "description": "\"Immediate switch\": RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization."
            }, 
            {
                "arm_group_label": "Nevirapine/Lamivudine/ plus other NNRTI", 
                "arm_group_type": "Active Comparator", 
                "description": "\"Delayed switch\": Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The study will be an open-label, pilot study in virologically suppressed patients comparing\n      the efficacy, safety and tolerability of two Antiretroviral regimen strategies:\n\n      Arm A: \"Immediate switch\" Rilpivirine/Emtricitabine/Tenofovir (single tablet formulation\n      (STF))at randomization\n\n      Arm B: \"Delayed switch\" Continue Nevirapine/Lamivudine/other Nucleoside reverse\n      transcriptase inhibitor (NRTI)through 24 weeks then switch to STF of\n      Rilpivirine/emtrictabine/tenofovir and followed through 48 weeks."
        }, 
        "brief_title": "Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "detailed_description": {
            "textblock": "The current study is designed to be the first study to compare a continued nevirapine-based\n      regimen to a switch to the FDC of rilpivirine/emtricitabine/tenofovir. Rwanda is a model\n      country for implementation of newer approaches to more innovative ART strategies with an\n      excellent National HIV Treatment program in place but has limited experience with clinical\n      trials and as with most African countries has no clinical experience with Rilpivirine in\n      treating HIV infected adults."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by\n             Western blot at any time prior to study entry. A second antibody test by a method\n             other than ELISA is acceptable as an alternative confirmatory test or a previous\n             detectable HIV RNA level\n\n          -  HIV RNA level below the limit of quantification of the viral load assay in use\n             in-country within the last 12 months\n\n          -  Screening HIV RNA level below the limit of quantification as defined by the local\n             assay\n\n          -  At least twelve months of stable first-line antiretroviral therapy consisting of\n             nevirapine and 2 nRTIs approved by the Rwandan HIV Treatment guidelines. (No prior\n             changes in ART are allowed)\n\n          -  Enrolled in the Rwanda National ART Program with no in-country transfer within the\n             program.\n\n          -  Negative TB symptom screen or eligible based on algorithm outlined in\n\n          -  Laboratory values obtained within 30 days prior to study entry:\n\n               -  Hemoglobin greater than 8.0 g/dL\n\n               -  Platelet count  greater than 40,000/mm3\n\n               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase less than 5 X ULN\n\n               -  Total bilirubin less than 2.5 x ULN\n\n               -  Calculated creatinine clearance greater than 60 mL/min as estimated by the\n                  Cockcroft-Gault equation:\n\n                    -  Ability to meet the nutritional requirements for rilpivirine; largest meal\n                       should consist of at least 400 total kcals and 117 kcals of fat (13 grams)\n                       to be assessed at screening.\n\n                    -  For women of reproductive potential, negative serum or urine pregnancy test\n                       within 4 weeks of initiating study medications and a negative urine\n                       pregnancy test at the entry visit prior to randomization.\n\n          -  \"Women of reproductive potential\" is defined as women who have not been\n             post-menopausal for at least 24 consecutive months (i.e., who have had menses within\n             the preceding 24 months) and have not undergone surgical sterilization (e.g.,\n             hysterectomy, bilateral oophorectomy, or tubal ligation).\n\n          -  Age greater than18 years.\n\n          -  Ability and willingness of subject to give informed consent.\n\n        Exclusion Criteria:\n\n          -  History of on-treatment virologic failure (defined as HIV RNA level greater than 200\n             copies/mL at or after 6 months of antiretroviral therapy)\n\n          -  Any change in prior ART.\n\n          -  Currently breastfeeding.\n\n          -  Active tuberculosis.\n\n          -  Serious illness requiring systemic treatment and/or hospitalization until candidate\n             either completes therapy or is clinically stable on therapy, in the opinion of the\n             site investigator, for at least 14 days prior to study entry.\n\n          -  NOTE: Isolated cutaneous Kaposi's Sarcoma, oral candidiasis, vaginal candidiasis,\n             mucocutaneous herpes simplex, and other non-serious illnesses (as judged by the site\n             investigator) have no restriction.\n\n          -  Known allergy/sensitivity to study drugs or their formulations.\n\n          -  Active drug or alcohol use or dependence that, in the opinion of the site\n             investigator, would interfere with adherence to study requirements.\n\n          -  Requirement for any current medications that are prohibited with any study treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104700", 
            "org_study_id": "Near Rwanda", 
            "secondary_id": "ISR-In-US-264-0123"
        }, 
        "intervention": {
            "arm_group_label": [
                "Rilpivirine/Emtricitabine/Tenofovir", 
                "Nevirapine/Lamivudine/ plus other NNRTI"
            ], 
            "description": "Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday", 
            "intervention_name": "Rilpivirine/Emtricitabine/Tenofovir", 
            "intervention_type": "Drug", 
            "other_name": "Complera"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Nevirapine", 
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Emtricitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "HIV", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "serayange@yahoo.fr", 
                "last_name": "Eric Seruyange, MD"
            }, 
            "contact_backup": {
                "email": "uwifranco@gmail.com", 
                "last_name": "Francois Uwinkindi, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Kinombe", 
                    "country": "Rwanda"
                }, 
                "name": "Rwanda Military Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Sabin Nsanzamana, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eric Seruyange, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Rwanda"
        }, 
        "number_of_arms": "2", 
        "official_title": "Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)\"", 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Andrew Zolopa, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Rwanda: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare proportion of subjects successfully maintaining a plasma viral load <200 copies /mL at week 24 in subjects randomized to rilpivirine/emtricitabine/tenofovir vs. in those randomized to initially continue nevirapine-based ART in this pilot study.", 
            "measure": "Explore Efficacy", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104700"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Andrew Zolopa", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "To compare between arms the probability of having an HIV RNA level <50 and <400 copies/mL at 24 weeks", 
            "measure": "HIV RNA levels", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Rwanda Biomedical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Gilead Sciences", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Andrew Zolopa", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}